Reuters logo
BRIEF-Astrazeneca says durvalumab gets FDA's priority review status in bladder cancer
December 9, 2016 / 3:32 PM / a year ago

BRIEF-Astrazeneca says durvalumab gets FDA's priority review status in bladder cancer

Dec 9 (Reuters) - Astrazeneca Plc :

* US FDA has accepted first biologics license application for durvalumab

* US FDA granted priority review status with a prescription drug user fee act (PDUFA) set for Q2 of 2017.

* Currently has more than 30 ongoing durvalumab clinical trials in combination with other io agents and targeted therapies. Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +91 80 6749 1136)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below